RENOVORX INC

Explore RenovoRx’s TAMP platform and Phase III TIGeR-PaC trial in our virtual webinar—discover how targeted micro‑perfusion could change pancreatic cancer treatment.

RenovoRx closes $10 M oversubscribed private placement, boosting funding for its solid‑tumor and pancreatic‑cancer programs and strengthening investor confidence.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company making strides in cancer treatment with its innovative approach to localized therapies for solid tumors and pancreatic cancer, positioning it as a promising player in the healthcare sector.

RenovoRx Inc.’s financial performance is marked by a 28% revenue surge, but also persistent losses and a struggle to meet revenue expectations, leaving investors and analysts to weigh the company’s potential for growth and profitability.